Lung Cancer

Nathan Pennell, MD, PhD, discusses challenges with next-generation sequencing in lung cancer.

Data suggest that up to 95% of patients with lung cancer score below the fiftieth percentile on sexual function during and after completion of cancer-directed therapy.

Charles M. Rudin, MD, PhD, discusses the design of the phase 3 KEYNOTE-604 trial in extensive-stage small cell lung cancer.

Matthew Schabath, PhD, discusses the use of peritumoral and intratumoral radiomic features, where investigators created a model that identified patients with early-stage lung cancer at high risk of experiencing poor survival outcomes.

Solange Peters, MD, discusses the promising clinical activity observed with trastuzumab deruxtecan in patients with HER2-mutated NSCLC, next steps for research, and other exciting lung cancer data.

Minimally invasive tool uses robotic technology to enable earlier, more accurate diagnosis of lung nodules.

Edgardo S. Santos, MD, discusses the data that led to the approval of the combination of ramucirumab and erlotinib in EGFR-mutant metastatic non–small cell lung cancer and shared his thoughts on its utility in the frontline setting.

Paul A. Bunn, Jr, MD, discusses how fam-trastuzumab deruxtecan-nxki could provide patients with metastatic non–small cell lung cancer who harbor HER2 exon 20 insertion mutations and high HER2 expression a more specific and less toxic treatment compared with platinum doublet chemotherapy.

Julie R. Brahmer, MD, discusses the details of the DESTINY-Lung01 trial, as well as remaining questions that could be answered with further research.

In our exclusive interview, Alexander Drilon, MD, discusses some of the historical challenges of targeting KRAS and provided perspective on available and anticipated data with AMG 510 in non–small cell lung cancer.

Solange Peters, MD,​ PhD, discusses ongoing research with ​fam-trastuzumab deruxtecan​-nxki (Enhertu; ​DS-8201) in patients with HER2-mutated non–small cell lung cancer.

The Japanese Ministry of Health, Labor, and Welfare has approved capmatinib for patients with MET exon 14 skipping mutation–positive advanced and/or recurrent unresectable non–small cell lung cancer.

Nathan A. Pennell, MD, PhD, discusses the significance of findings from the DESTINY-Lung01 trial in non–small cell lung cancer.